UNLABELLED The treatment of patients with high-grade malignant glioma still represents an unsolved clinical problem. We report the treatment of 3 patients who had World Health Organization grade IV recurrent glioblastoma: a 23-y-old woman and 2 men aged 61 and 62 y. METHODS All 3 patients were treated with the somatostatin receptor radiopharmaceutical (90)Y-labeled [1,4,7,10-tetraazacyclodode...

PURPOSE Patients with neuroendocrine tumors (NET) often present with disseminated liver metastases and can be treated with a number of different nuclides or nuclide combinations in peptide receptor radionuclide therapy (PRRT) depending on tumor load and lesion diameter. For quantification of disseminated liver lesions, semi-automatic lesion detection is helpful to determine tumor burden and tum...

Rational To validate a population-based input function (PBIF) model that alleviates the need for scanning since injection time in dynamic whole-body (WBdyn) PET. Methods Thirty-seven patients with suspected/known well-differentiated neuroendocrine tumors were included (GAPETNET trial NTC03576040). All WBdyn 68Ga-DOTATOC-PET/CT acquisitions performed on digital PET system (one heart-centered 6 m...

We report the case of a female patient who had a neuroendocrine tumor in the pancreatic tail. Followup using (68)Ga DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC) positron-emission tomography (PET)/computed tomography (CT) detected a round, well-circumscribed nodular mass that exhibited positive somatostatin receptors. This finding was highly suggestive of an accessory spleen; however, due to the sl...